EPS for XOMA (XOMA) Expected At $-0.49; Nexa Resources S.A.HARES (NEXA) Shorts Decreased By 12.59%

XOMA Corporation (NASDAQ:XOMA) Logo

Nexa Resources S.A.HARES (NYSE:NEXA) had a decrease of 12.59% in short interest. NEXA’s SI was 225,000 shares in February as released by FINRA. Its down 12.59% from 257,400 shares previously. With 57,300 avg volume, 4 days are for Nexa Resources S.A.HARES (NYSE:NEXA)’s short sellers to cover NEXA’s short positions. The SI to Nexa Resources S.A.HARES’s float is 0.18%. The stock decreased 0.11% or $0.01 during the last trading session, reaching $9.32. About 22,568 shares traded. Nexa Resources S.A. (NYSE:NEXA) has declined 27.02% since February 12, 2018 and is downtrending. It has underperformed by 27.02% the S&P500. Some Historical NEXA News: 06/03/2018 – OVERALL, TRUMP TARIFFS `DISASTER’ FOR ECONOMIC GROWTH: NEXA CEO; 06/03/2018 – BENCHMARK ZINC TREATMENT CHARGES LIKELY $140-$150 IN ’18: NEXA; 12/04/2018 – Acadian Asset Buys New 1.1% Position in Nexa Resources SA; 03/05/2018 – Nexa Resources Selects Unisys to Drive Company’s Digital Transformation; 06/03/2018 – NEXA COULD SEE SHORT-TERM BENEFIT IF TRUMP INTRODUCES 25 PERCENT TARIFF ON STEEL, IF NEXA INCREASES SALES OF ITS ZINC IN LATIN AMERICA -CEO; 28/05/2018 – NEXA RESOURCES TAKING STEPS TO MITIGATE IMPACT OF BRAZIL STRIKE; 11/04/2018 – Nexa Resources S.A. to Host Conference Call to Discuss First Quarter 2018 Results; 30/04/2018 – Nexa Resources S.A. Announces Filing of Form 20-F for the Fiscal Year Ended 2017 and Publication of Mineral Reserves and Minera; 14/05/2018 – ITAU BBA EXITED LTM, AGRO, CZZ, NEXA, GGAL IN 1Q: 13F; 06/03/2018 – NEXA CEO SAYS ZINC PRICES COULD BE SUPPORTED AT $3500-$3600/TON

Analysts expect XOMA Corporation (NASDAQ:XOMA) to report $-0.49 EPS on March, 6.They anticipate $0.33 EPS change or 206.25% from last quarter’s $-0.16 EPS. After having $-0.55 EPS previously, XOMA Corporation’s analysts see -10.91% EPS growth. The stock increased 0.90% or $0.11 during the last trading session, reaching $12.35. About 24,559 shares traded. XOMA Corporation (NASDAQ:XOMA) has declined 55.68% since February 12, 2018 and is downtrending. It has underperformed by 55.68% the S&P500. Some Historical XOMA News: 09/05/2018 – XOMA CORP XOMA.O – QTRLY SHR LOSS $0.46; 08/05/2018 – XOMA REPORTS $20M CREDIT LINE TO ADVANCE ROYALTY-AGGREGATOR; 08/05/2018 – XOMA CORP – CO, UNITS ENTERED LOAN AND SECURITY AGREEMENT UNDER WHICH LENDER AGREED TO LEND UP TO $20.0 MLN IN A SERIES OF TERM LOANS – SEC FILING; 08/05/2018 – XOMA CORP – CO MAY BORROW ADDITIONAL $20.0 MLN FROM LENDER SUBJECT TO CERTAIN CONDITIONS; 19/04/2018 – DJ XOMA Corporation, Inst Holders, 1Q 2018 (XOMA); 09/04/2018 – Xoma at HC Wainwright Global Biotechnology Conference Tomorrow; 07/03/2018 – XOMA CORP. FILES $300M MIXED SECURITIES SHELF; 20/03/2018 – Investor Expectations to Drive Momentum within Key Energy Services, XOMA, Goldman Sachs BDC, Echo Global Logistics, Ellington R; 09/05/2018 – XOMA 1Q Loss/Shr 46c; 09/05/2018 – XOMA 1Q LOSS/SHR 46C, EST. LOSS/SHR 52C

XOMA Corporation discovers, develops, and commercializes antibody therapeutics in the United States, Europe, and the Asia Pacific. The company has market cap of $107.21 million. The company's product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia. It currently has negative earnings. The Company’s preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy.

More notable recent XOMA Corporation (NASDAQ:XOMA) news were published by: Nasdaq.com which released: “XOMA Announces Proposed Rights Offering – Nasdaq” on November 07, 2018, also Globenewswire.com with their article: “XOMA Announces Closing of Rights Offering Nasdaq:XOMA – GlobeNewswire” published on December 18, 2018, Seekingalpha.com published: “Xoma: Buy, Sell Or Hold? – Seeking Alpha” on November 27, 2018. More interesting news about XOMA Corporation (NASDAQ:XOMA) were released by: Globenewswire.com and their article: “XOMA Announces Commencement of Rights Offering Nasdaq:XOMA – GlobeNewswire” published on November 19, 2018 as well as Globenewswire.com‘s news article titled: “XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte – GlobeNewswire” with publication date: September 21, 2018.

XOMA Corporation (NASDAQ:XOMA) Ratings Chart